Ameriprise Financial Inc Nektar Therapeutics Transaction History

Ameriprise Financial Inc

  • $364 Billion
  • Q2 2024

A detailed history of Ameriprise Financial Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Ameriprise Financial Inc holds 291,924 shares of NKTR stock, worth $341,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares
291,924
Previous 220,596 32.33%
Holding current value
$341,551
Previous $205,000 76.1%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.9 - $1.83 $64,195 - $130,530
71,328 Added 32.33%
291,924 $361,000
Q1 2024

May 15, 2024
SELL
$0.49 - $0.96 $113,428 - $222,226
-231,486 Reduced 51.2%
220,596 $205,000
Q4 2023

Feb 14, 2024
SELL
$0.42 - $0.57 $15,253 - $20,701
-36,318 Reduced 7.44%
452,082 $253,000
Q3 2023

Nov 14, 2023
SELL
$0.51 - $1.05 $1,020 - $2,100
-2,000 Reduced 0.41%
488,400 $293,000
Q2 2023

Aug 14, 2023
SELL
$0.53 - $1.03 $267,104 - $519,089
-503,970 Reduced 50.68%
490,400 $284,000
Q1 2023

May 15, 2023
BUY
$0.64 - $3.15 $64,909 - $319,476
101,421 Added 11.36%
994,370 $696,000
Q4 2022

Feb 14, 2023
BUY
$2.03 - $4.28 $200,827 - $423,420
98,930 Added 12.46%
892,949 $2.02 Million
Q3 2022

Nov 14, 2022
BUY
$3.04 - $5.14 $88,457 - $149,563
29,098 Added 3.8%
794,019 $2.54 Million
Q2 2022

Aug 15, 2022
SELL
$3.17 - $6.17 $50,685 - $98,652
-15,989 Reduced 2.05%
764,921 $2.91 Million
Q1 2022

May 16, 2022
SELL
$4.16 - $13.72 $78,158 - $257,771
-18,788 Reduced 2.35%
780,910 $4.21 Million
Q4 2021

Feb 14, 2022
BUY
$10.83 - $18.41 $5.68 Million - $9.66 Million
524,597 Added 190.69%
799,698 $10.8 Million
Q3 2021

Nov 15, 2021
SELL
$13.07 - $18.84 $181,333 - $261,386
-13,874 Reduced 4.8%
275,101 $4.94 Million
Q2 2021

Aug 16, 2021
SELL
$16.52 - $20.4 $27.7 Million - $34.2 Million
-1,677,263 Reduced 85.3%
288,975 $4.96 Million
Q1 2021

May 17, 2021
BUY
$16.56 - $25.46 $27.4 Million - $42.2 Million
1,657,578 Added 537.02%
1,966,238 $39.3 Million
Q4 2020

Feb 12, 2021
SELL
$15.77 - $19.03 $290,798 - $350,913
-18,440 Reduced 5.64%
308,660 $5.25 Million
Q3 2020

Nov 16, 2020
SELL
$16.59 - $24.79 $334,587 - $499,964
-20,168 Reduced 5.81%
327,100 $5.43 Million
Q2 2020

Aug 14, 2020
SELL
$16.86 - $23.44 $106,133 - $147,554
-6,295 Reduced 1.78%
347,268 $8.04 Million
Q1 2020

May 15, 2020
SELL
$14.47 - $27.96 $411,251 - $794,651
-28,421 Reduced 7.44%
353,563 $6.31 Million
Q4 2019

Feb 14, 2020
BUY
$15.87 - $23.12 $4.92 Million - $7.16 Million
309,864 Added 429.65%
381,984 $8.25 Million
Q3 2019

Nov 14, 2019
BUY
$16.91 - $36.27 $234,169 - $502,266
13,848 Added 23.76%
72,120 $1.32 Million
Q2 2019

Aug 14, 2019
SELL
$31.0 - $36.3 $711,915 - $833,629
-22,965 Reduced 28.27%
58,272 $2.07 Million
Q1 2019

May 15, 2019
BUY
$31.58 - $46.35 $341,127 - $500,672
10,802 Added 15.34%
81,237 $2.73 Million
Q4 2018

Feb 14, 2019
SELL
$30.43 - $56.65 $448,933 - $835,757
-14,753 Reduced 17.32%
70,435 $2.32 Million
Q3 2018

Nov 14, 2018
BUY
$46.46 - $68.49 $415,538 - $612,574
8,944 Added 11.73%
85,188 $5.19 Million
Q2 2018

Aug 14, 2018
SELL
$46.25 - $104.45 $1.97 Million - $4.45 Million
-42,606 Reduced 35.85%
76,244 $3.66 Million
Q1 2018

May 15, 2018
SELL
$57.4 - $108.44 $44.7 Million - $84.5 Million
-779,616 Reduced 86.77%
118,850 $12.6 Million
Q4 2017

Feb 12, 2018
SELL
$23.02 - $60.5 $1.07 Million - $2.81 Million
-46,417 Reduced 4.91%
898,466 $53.7 Million
Q3 2017

Nov 07, 2017
BUY
$17.79 - $24.0 $16.8 Million - $22.7 Million
944,883
944,883 $22.7 Million

Others Institutions Holding NKTR

# of Institutions
140
Shares Held
135M
Call Options Held
32.8K
Put Options Held
55.5K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email